Doreen Nakku1, Victoria Nyaiteera2, Evelyn Llowet2, Dennis Nanseera3, Gladys Nakalema4, Brian Westerberg5, Francis Bajunirwe6. 1. Department of Ear, Nose and Throat, Mbarara University of Science and Technology, P.O Box 1410, Mbarara, Uganda. Electronic address: daurynez@gmail.com. 2. Department of Ear, Nose and Throat, Mbarara University of Science and Technology, P.O Box 1410, Mbarara, Uganda. 3. Pediatric HIV Clinic, Mbarara Regional Referral Hospital, P.O Box 40, Mbarara, Uganda. 4. Department of Educational Psychology, Mbarara University of Science and Technology, P.O Box 1410, Mbarara, Uganda. 5. Division of Otology and Neurotology, University of British Columbia, St. Paul's Hospital, 1081 Burrard Street, Vancouver, BC, Canada. 6. Department of Community Health, Mbarara University of Science and Technology, P.O Box 1410, Mbarara, Uganda.
Abstract
INTRODUCTION: Pediatric HIV infection and treatment may increase the risk for hearing loss (HL), both sensorineural (SNHL) and conductive hearing loss (CHL). There is limited data on this subject, especially from sub Saharan Africa. The aim of this study was therefore to compare the prevalence of hearing loss among HIV positive and negative children, to determine the types of hearing loss and whether Nevirapine (NVP) based antiretroviral therapy (ART) is associated with HL. METHODS: We conducted a cross sectional study at two tertiary health facilities in south western Uganda. We consecutively enrolled 79 HIV negative and 148 HIV positive children aged between 6 and 12 years. Inclusion criteria were completion of written consent, ability to follow instructions to perform an audiogram and absence of congenital HL. We conducted hearing screening using the iPad Shoebox® audiometer, and confirmatory assessments were conducted using pure tone audiometry. Hearing was classified as either normal hearing, CHL, SNHL or mixed. RESULTS: Of the 227 children enrolled, 115 (50.7%) were female. The mean age was 9.2 years (median = 9). Based on self-report, frequency of HL among HIV positive children was 6.8% and 20.3% among HIV negative children (p=<0.01). Using objective measures, prevalence of HL among the HIV positive children was 8.8% compared to 10.1% among the HIV negative children (p = 0.74). CHL was generally more frequent than SNHL but SNHL occurred more frequently among HIV positive (7.4%) compared to HIV negative children (3.8%). No association was found between NVP based ART and HL (p = 0.41). Logistic regression showed that older age of the child (p = 0.01), previous ear infection (p=<0.01), tuberculosis (TB) treatment (p=<0.01) and long term duration on ART (p=<0.01) were significantly associated with HL. Age (p = 0.02), previous ear infection (p = 0.01) and TB treatment (p = 0.005) remained significant in the multiple regression model. CONCLUSION: Prevalence of HL is similar among HIV positive and negative children. Older age of the child, previous ear infection, use of TB drugs and long duration on ART among the HIV positive children increase the odds of having hearing loss among children. However, use of NVP was not associated with HL.
INTRODUCTION:Pediatric HIV infection and treatment may increase the risk for hearing loss (HL), both sensorineural (SNHL) and conductive hearing loss (CHL). There is limited data on this subject, especially from sub Saharan Africa. The aim of this study was therefore to compare the prevalence of hearing loss among HIV positive and negative children, to determine the types of hearing loss and whether Nevirapine (NVP) based antiretroviral therapy (ART) is associated with HL. METHODS: We conducted a cross sectional study at two tertiary health facilities in south western Uganda. We consecutively enrolled 79 HIV negative and 148 HIV positive children aged between 6 and 12 years. Inclusion criteria were completion of written consent, ability to follow instructions to perform an audiogram and absence of congenital HL. We conducted hearing screening using the iPad Shoebox® audiometer, and confirmatory assessments were conducted using pure tone audiometry. Hearing was classified as either normal hearing, CHL, SNHL or mixed. RESULTS: Of the 227 children enrolled, 115 (50.7%) were female. The mean age was 9.2 years (median = 9). Based on self-report, frequency of HL among HIV positive children was 6.8% and 20.3% among HIV negative children (p=<0.01). Using objective measures, prevalence of HL among the HIV positive children was 8.8% compared to 10.1% among the HIV negative children (p = 0.74). CHL was generally more frequent than SNHL but SNHL occurred more frequently among HIV positive (7.4%) compared to HIV negative children (3.8%). No association was found between NVP based ART and HL (p = 0.41). Logistic regression showed that older age of the child (p = 0.01), previous ear infection (p=<0.01), tuberculosis (TB) treatment (p=<0.01) and long term duration on ART (p=<0.01) were significantly associated with HL. Age (p = 0.02), previous ear infection (p = 0.01) and TB treatment (p = 0.005) remained significant in the multiple regression model. CONCLUSION: Prevalence of HL is similar among HIV positive and negative children. Older age of the child, previous ear infection, use of TB drugs and long duration on ART among the HIV positive children increase the odds of having hearing loss among children. However, use of NVP was not associated with HL.
Authors: Anni Taipale; Tuula Pelkonen; Marko Taipale; Irmeli Roine; Luis Bernardino; Heikki Peltola; Anne Pitkäranta Journal: Eur Arch Otorhinolaryngol Date: 2011-03-25 Impact factor: 2.503
Authors: Susan Hrapcak; Hannah Kuper; Peter Bartlett; Akash Devendra; Atupele Makawa; Maria Kim; Peter Kazembe; Saeed Ahmed Journal: PLoS One Date: 2016-08-23 Impact factor: 3.240
Authors: Ana Carla Leite Romero; Lívia Marangoni Alfaya; Alina Sanches Gonçales; Ana Claudia Figueiredo Frizzo; Myriam de Lima Isaac Journal: Int Arch Otorhinolaryngol Date: 2016-03-14
Authors: Janaina Oliveira Bentivi; Conceição de Maria Pedrozo E Silva de Azevedo; Monique Kelly Duarte Lopes; Savya Cybelle Milhomem Rocha; Paula Cristina Ribeiro E Silva; Valeria Maciel Costa; Ana Beatriz Sousa Costa Journal: J Pediatr (Rio J) Date: 2020-01-03 Impact factor: 2.990